The high-profile hedge fund run by veteran stockpicker Phil King has slashed the value of its stake in Opthea by two-thirds after the eye treatment biotech said it faced collapse after the failure of a key clinical trial.
While the company last traded at 60¢ per share, before it entered an extended pause ahead of the publication of the trial result, Regal Partners told investors it was now valuing Opthea at 20¢ per share.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。